Business Model Breakdown
How Keros Therapeutics Inc Makes Money
KROS
Market Cap
$208M
Annual Revenue
$33M
Profit Margin
-256.6%
Employees
148
The Short Version
Keros Therapeutics is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel treatments for patients with hematologic and rare diseases. It operates by developing proprietary small molecule and protein therapeutics that modulate the transforming growth factor-beta (TGF-ß) superfamily of proteins. The company aims to generate revenue through licensing agreements with larger pharmaceutical partners for its drug candidates (e.g., Takeda for KER-012) and, ultimately, through direct sales of its own approved products (e.g., KER-050). Its current financial model is heavily reliant on capital raises and non-recurring licensing payments to fund extensive research and development.
Where the Revenue Comes From
Licensing and collaboration revenue (e.g., Takeda agreement, ~0% of Q1 2026 revenue)
Future product sales (currently 0% of revenue)
Who buys: Currently, its primary 'customer' is licensing partners. In the future, its customers would be healthcare providers and patients (via insurance/pharmacies) for its commercialized therapeutics.
Why It Works (Competitive Advantages)
- ✔Differentiated mechanism of action via TGF-beta pathway modulation, potentially offering superior efficacy or safety profiles.
- ✔Validated platform through the Takeda licensing deal for elritercept (KER-012), now entering Phase 3.
- ✔Deep pipeline targeting multiple unmet medical needs across various indications beyond initial lead assets.
Economic Moat: Narrow (Intangible Assets/IP (patents on novel compounds, proprietary research in TGF-beta pathway biology), Switching Costs (for physicians/patients if an effective therapy is established and integrated into treatment protocols))
What Our Analysis Says
DVR Score as of June 5, 2026
Keros Therapeutics still possesses significant long-term 10x potential due to its deep pipeline targeting large unmet medical needs via the validated TGF-beta pathway. The Takeda licensing deal for KER-012, now progressing to Phase 3, validates the platform and offers future milestones. However, recent Q1 2026 earnings were abysmal, showing a near 100% year-over-year revenue decline and a swing to a significant net loss, primarily due to the absence of prior-year license revenue. While the cash runway into H1 2028 provides a buffer, the substantial cash burn without a clear near-term revenue stream significantly increases financial risk. The company's valuation, despite being below cash per share, reflects the high uncertainty. Clinical trial risks remain paramount, and while pipeline progress is encouraging, the immediate financial picture is a major concern.